000 | 03586nam a22004575i 4500 | ||
---|---|---|---|
001 | vtls000540725 | ||
003 | RU-ToGU | ||
005 | 20210922081825.0 | ||
007 | cr nn 008mamaa | ||
008 | 160915s2014 xxk| s |||| 0|eng d | ||
020 |
_a9781447165033 _9978-1-4471-6503-3 |
||
024 | 7 |
_a10.1007/978-1-4471-6503-3 _2doi |
|
035 | _ato000540725 | ||
040 |
_aSpringer _cSpringer _dRU-ToGU |
||
050 | 4 | _aRC346-429.2 | |
072 | 7 |
_aMJN _2bicssc |
|
072 | 7 |
_aMED056000 _2bisacsh |
|
082 | 0 | 4 |
_a616.8 _223 |
245 | 1 | 0 |
_aLevodopa-Induced Dyskinesia in Parkinson's Disease _helectronic resource _cedited by Susan H. Fox, Jonathan M. Brotchie. |
260 |
_aLondon : _bSpringer London : _bImprint: Springer, _c2014. |
||
300 |
_aXII, 368 p. 12 illus., 11 illus. in color. _bonline resource. |
||
336 |
_atext _btxt _2rdacontent |
||
337 |
_acomputer _bc _2rdamedia |
||
338 |
_aonline resource _bcr _2rdacarrier |
||
505 | 0 | _aPhenomenology of Levodopa-Induced Dyskinesia -- Dyskinesia Rating Scales in Parkinson's Disease -- Epidemiology of Levodopa-Induced Dyskinesia -- Risk Factors for Levodopa-Induced Dyskinesia -- Pharmacological Treatment Options for Levodopa-Induced Dyskinesia -- Surgical Options for Levodopa-Induced Dyskinesia in Parkinson’s Disease -- Basal Ganglia Circuitry Models of L-DOPA-Induced Dyskinesia -- Basal Ganglia Circuitry Models of L-DOPA-Induced Dyskinesia -- Pharmacological Properties of Levodopa -- Dopamine Receptors and LID -- The Serotonergic System In Levodopa-Induced Dyskinesia -- The Opioid System in Levodopa-Induced Dyskinesia -- Glutamate Receptors and Levodopa-Induced Dyskinesia -- Cannabinoids and Levodopa-Induced Dyskinesia -- The Role of the Noradrenergic System and its Receptors In Levodopa-Induced Dyskinesia -- Involvement of the Cholinergic System in Levodopa-Induced Dyskinesia -- New Clinical Trials for Levodopa-Induced Dyskinesia -- Preclinical Models of Levodopa-Induced Dyskinesia -- Final Thoughts: Summary and Future Therapeutic Strategies in LID. | |
520 | _aThis book aims to provide a single reference source on levodopa-induced dyskinesias (LID) from ‘bench to bedside’. Initial chapters review the clinical features and phenomenology of LID with video examples; epidemiology and genetic risk factors for LID are covered as a background to understanding risk factors for developing LID. The following chapters cover the latest preclinical studies aiming to understand the pathophysiology of LID at the cellular, neurochemical, neurophysiological and circuitry level with detailed discussion of mechanisms and future directions to take the field forward; clinical studies from phase II to phase IV; ongoing RCTs in LID; and evidence-based medicine reviews of treatment options. Levodopa-Induced Dyskinesia in Parkinson’s Disease is aimed at an international audience of movement disorder neurologists; neuroscientists; trainees; and graduate and post-graduate students. | ||
650 | 0 |
_amedicine. _9566220 |
|
650 | 0 |
_aNeurosciences. _9302217 |
|
650 | 0 |
_aNeurology. _9303067 |
|
650 | 1 | 4 |
_aMedicine & Public Health. _9566221 |
650 | 2 | 4 |
_aNeurology. _9303067 |
650 | 2 | 4 |
_aNeurosciences. _9302217 |
700 | 1 |
_aFox, Susan H. _eeditor. _9445367 |
|
700 | 1 |
_aBrotchie, Jonathan M. _eeditor. _9445368 |
|
710 | 2 |
_aSpringerLink (Online service) _9143950 |
|
773 | 0 | _tSpringer eBooks | |
856 | 4 | 0 | _uhttp://dx.doi.org/10.1007/978-1-4471-6503-3 |
912 | _aZDB-2-SME | ||
999 | _c398422 |